Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Nov-Dec;62(6):667-669.
doi: 10.4103/ijd.IJD_496_17.

Author's reply

P Ravindra Babu  1 , A J S Pravin  2 , Gaurav Deshmukh  3 , Dhiraj Dhoot  3 , Aniket Samant  3 , Bhavesh Kotak  3
Affiliations

Author's reply

P Ravindra Babu et al. Indian J Dermatol. 2017 Nov-Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

References

    1. Levison ME, Levison JH. Pharmacokinetics and pharmacodynamics of antibacterial agents. Infect Dis Clin North Am. 2009;23:791–815. vii. - PMC - PubMed
    1. Sakai MR, May ER, Imerman PM, Felz C, Day TA, Carlson SA, et al. Terbinafine pharmacokinetics after single dose oral administration in the dog. Vet Dermatol. 2011;22:528–34. - PubMed
    1. Dolton MJ, Perera V, Pont LG, McLachlan AJ. Terbinafine in combination with other antifungal agents for treatment of resistant or refractory mycoses: Investigating optimal dosing regimens using a physiologically based pharmacokinetic model. Antimicrob Agents Chemother. 2014;58:48–54. - PMC - PubMed
    1. Villars V, Jones TC. Present status of the efficacy and tolerability of terbinafine (Lamisil) used systemically in the treatment of dermatomycoses of skin and nails. J Dermatolog Treat. 1990;1:33–8.
    1. [Last accessed on 2017 Sep 22]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020539s021lbl.pdf .

LinkOut - more resources